Why we should care about gas pockets in online adaptive MRgRT: a dosimetric evaluation.
MRgRT
dosimetry
gas pockets
online adaptive radiotherapy
relative electron density
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
08
2023
accepted:
27
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Contouring of gas pockets is a time consuming step in the workflow of adaptive radiotherapy. We would like to better understand which gas pockets electronic densitiy should be used and the dosimetric impact on adaptive MRgRT treatment. 21 CT scans of patients undergoing SBRT were retrospectively evaluated. Anatomical structures were contoured: Gross Tumour Volume (GTV), stomach (ST), small bowel (SB), large bowel (LB), gas pockets (GAS) and gas in each organ respectively STG, SBG, LBG. Average HU in GAS was converted in RED, the obtained value has been named as Gastrointestinal Gas RED (GIGED). Differences of average HU in GAS, STG, SBG and LBG were computed. Three treatment plans were calculated editing the GAS volume RED that was overwritten with: air RED (0.0012), water RED (1.000), GIGED, generating respectively APLAN, WPLAN and the GPLAN. 2-D dose distributions were analyzed by gamma analysis. Parameter called active gas volume (AGV) was calculated as the intersection of GAS with the isodose of 5% of prescription dose. Average HU value contained in GAS results to be equal to -620. No significative difference was noted between the average HU of gas in different organ at risk. Value of Gamma Passing Rate (GPR) anticorrelates with the AGV for each plan comparison and the threshold value for GPR to fall below 90% is 41, 60 and 139 cc for WPLANvsAPLAN, GPLANvsAPLAN and WPLANvsGPLAN respectively. GIGED is the right RED for Gastrointestinal Gas. Novel AGV is a useful parameter to evaluate the effect of gas pocket on dose distribution.
Identifiants
pubmed: 38023178
doi: 10.3389/fonc.2023.1280836
pmc: PMC10679396
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1280836Informations de copyright
Copyright © 2023 Nardini, Meffe, Galetto, Boldrini, Chiloiro, Romano, Panza, Bevacqua, Turco, Votta, Capotosti, Moretti, Gambacorta, Indovina and Placidi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2020 Feb;21(2):e74-e82
pubmed: 32007208
Front Oncol. 2021 Aug 30;11:748685
pubmed: 34527596
Phys Med Biol. 2000 Aug;45(8):2163-83
pubmed: 10958187
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
Radiat Oncol. 2019 Apr 29;14(1):71
pubmed: 31036034
Phys Med. 2018 Sep;53:80-85
pubmed: 30241758
Phys Med. 2021 May;85:72-78
pubmed: 33979726
Radiother Oncol. 2022 Nov;176:31-38
pubmed: 36063982
J Appl Clin Med Phys. 2020 Jul;21(7):144-152
pubmed: 32445292
Med Phys. 2016 Jul;43(7):4040
pubmed: 27370123
Br J Radiol. 2021 Mar 01;94(1119):20200239
pubmed: 33353402
Med Phys. 2021 Jan;48(1):414-426
pubmed: 33164217
Front Oncol. 2021 Apr 01;11:616027
pubmed: 33869001
Eur Urol. 2022 Aug;82(2):149-151
pubmed: 35031164
Med Phys. 2020 Jun;47(6):2506-2515
pubmed: 32145087
Med Phys. 2015 Dec;42(12):7182-9
pubmed: 26632072
Int J Radiat Oncol Biol Phys. 2023 Nov 15;117(4):799-808
pubmed: 37210048
Med Phys. 2003 Sep;30(9):2455-64
pubmed: 14528967
Radiother Oncol. 2006 May;79(2):211-7
pubmed: 16698097
Radiother Oncol. 2020 Dec;153:205-212
pubmed: 33075394
Med Phys. 2020 Jun;47(6):2484-2494
pubmed: 32144781
Br J Radiol. 2018 Feb;91(1083):20170512
pubmed: 29166133
J Clin Med. 2022 Jan 12;11(2):
pubmed: 35054061